Phase I/II study of novel oral fluoropyrimidine S-1 in combination with oxaliplatin (SOX) as first-line chemotherapy for metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Tahara, M. [1 ]
Yamada, Y. [2 ]
Ohtsu, A. [1 ]
Shirao, K. [2 ]
Shimada, Y. [2 ]
Sasaki, Y. [3 ]
Yamamoto, W. [3 ]
Satoh, T. [4 ]
Okamoto, W. [4 ]
Tanigawara, Y. [5 ]
机构：
[1] Natl Canc Ctr Hosp E, Div Endoscopy & GI Oncol, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr, Gastrointestinal Oncol Div, Tokyo, Japan
[3] Saitama Med Univ Int, Med Ctr, Dept Clin Oncol, Saitama, Japan
[4] Kinki Univ, Sch Med, Dept Med Oncol, Osaka, Japan
[5] Keio Univ Hosp, Dept Pharm, Tokyo, Japan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70989-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3061
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [31] S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
    Kim, S. Y.
    Hong, Y. S.
    Shim, E. K.
    Kong, S-Y
    Shin, A.
    Baek, J. Y.
    Jung, K. H.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1420 - 1427
  • [32] S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
    S Y Kim
    Y S Hong
    E K Shim
    S-Y Kong
    A Shin
    J Y Baek
    K H Jung
    British Journal of Cancer, 2013, 109 : 1420 - 1427
  • [33] A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
    Vasile, E.
    Masi, G.
    Fornaro, L.
    Cupini, S.
    Loupakis, F.
    Bursi, S.
    Petrini, I.
    Di Donato, S.
    Brunetti, I. M.
    Ricci, S.
    Antonuzzo, A.
    Chiara, S.
    Amoroso, D.
    Andreuccetti, M.
    Falcone, A.
    BRITISH JOURNAL OF CANCER, 2009, 100 (11) : 1720 - 1724
  • [34] A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
    E Vasile
    G Masi
    L Fornaro
    S Cupini
    F Loupakis
    S Bursi
    I Petrini
    S Di Donato
    I M Brunetti
    S Ricci
    A Antonuzzo
    S Chiara
    D Amoroso
    M Andreuccetti
    A Falcone
    British Journal of Cancer, 2009, 100 : 1720 - 1724
  • [35] Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer
    Zang, D. Y.
    Lee, B. H.
    Park, H. -C.
    Song, H. H.
    Kim, H. J.
    Jung, J. Y.
    Kim, J. H.
    Kim, H. Y.
    Kwon, J. H.
    Hwang, S. W.
    Park, S. R.
    Park, C. H.
    Kim, K. O.
    Kim, M. -J.
    Jang, K. M.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 892 - 896
  • [36] Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
    Koizumi, W.
    Takiuchi, H.
    Yamada, Y.
    Boku, N.
    Fuse, N.
    Muro, K.
    Komatsu, Y.
    Tsuburaya, A.
    ANNALS OF ONCOLOGY, 2010, 21 (05) : 1001 - 1005
  • [37] PHASE II STUDY WITH DOCETAXEL, OXALIPLATIN AND S-1 COMBINATION CHEMOTHERAPY FOR PATIENTS WITH METASTATIC GASTRIC CANCER
    Zang, D. Y.
    Kang, Y.
    Ryoo, B.
    Ryu, M.
    Lee, S. S.
    Song, H. H.
    Jung, J. Y.
    Kwon, J. H.
    Kim, H. S.
    Choi, D. R.
    ANNALS OF ONCOLOGY, 2010, 21 : 261 - 261
  • [38] EFFICACY AND SAFETY OF CETUXIMAB, OXALIPLATIN AND CAPECITABINE AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF A PHASE II STUDY
    Barroso, S.
    Sanches, E.
    Ferreira, J.
    Passos, M.
    Sa, A.
    Nabico, R.
    SottoMayor, C.
    Santo, Espirito J.
    San-Bento, R.
    ANNALS OF ONCOLOGY, 2009, 20 : 65 - 65
  • [39] Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): Results of a phase II study
    Barroso, S. A.
    Sanches, E.
    Ferreira, M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
    Whyte, S.
    Pandor, A.
    Stevenson, M.
    Rees, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
12345